# Immunoprecise Antibodies Current Ratio vs. Z Score

IPA | Stock | ## USD 4.94 0.37 6.97% |

Immunoprecise |

Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 132.4 M | Quarterly Revenue Growth YOY 0.022 | Return On Assets (0.20) | Return On Equity (0.38) |

The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

## Immunoprecise Antibodies Z Score vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Immunoprecise Antibodies's current stock value. Our valuation model uses many indicators to compare Immunoprecise Antibodies value to that of its competitors to determine the firm's financial worth. Immunoprecise Antibodies is rated**below average**in current ratio category among related companies. It is rated

**third**overall in z score category among related companies totaling about 9.96 of Z Score per Current Ratio. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunoprecise Antibodies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunoprecise Antibodies' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunoprecise Antibodies' earnings, one of the primary drivers of an investment's value.

## Immunoprecise Z Score vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Immunoprecise Antibodies |
| = | 5.06 X |

Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Immunoprecise Antibodies |
| = | 50.4 |

To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.

## Immunoprecise Z Score Comparison

Immunoprecise Antibodies is currently under evaluation in z score category among related companies.

## Immunoprecise Antibodies Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Immunoprecise Antibodies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunoprecise Antibodies will eventually generate negative long term returns. The profitability progress is the general direction of Immunoprecise Antibodies' change in net profit over the period of time. It can combine multiple indicators of Immunoprecise Antibodies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies is traded on NASDAQ Exchange in the United States.

## Immunoprecise Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Immunoprecise Antibodies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunoprecise Antibodies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunoprecise Antibodies' important profitability drivers and their relationship over time.

## Use Immunoprecise Antibodies in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunoprecise Antibodies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunoprecise Antibodies will appreciate offsetting losses from the drop in the long position's value.## Immunoprecise Antibodies Pair Trading

### Immunoprecise Antibodies Pair Trading Analysis

The ability to find closely correlated positions to Immunoprecise Antibodies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunoprecise Antibodies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunoprecise Antibodies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunoprecise Antibodies to buy it.

The correlation of Immunoprecise Antibodies is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunoprecise Antibodies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunoprecise Antibodies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Immunoprecise Antibodies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.## Use Investing Themes to Complement your Immunoprecise Antibodies position

In addition to having Immunoprecise Antibodies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.## Did You Try This Idea?

### Run Utilities Thematic Idea Now

##### Utilities

Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. The Utilities theme has 30 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.

View All Next | Launch |

Please see Risk vs Return Analysis. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

## Complementary Tools for analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.

Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device | Go | |

Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets | Go | |

Volatility AnalysisGet historical volatility and risk analysis based on latest market data | Go | |

Fund ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges | Go | |

Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios | Go |

To fully project Immunoprecise Antibodies' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Immunoprecise Antibodies at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Immunoprecise Antibodies' income statement, its balance sheet, and the statement of cash flows.